+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Antiangiogenic therapy: preclinical premise and promise: Biological Basis for Antiangiogenic Therapy, Milan, Italy, 810 November 1999



Antiangiogenic therapy: preclinical premise and promise: Biological Basis for Antiangiogenic Therapy, Milan, Italy, 810 November 1999



Molecular Medicine Today 6(5): 188-189




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 062862222

Download citation: RISBibTeXText

DOI: 10.1016/s1357-4310(00)01672-5


Related references

Biological basis for anti-angiogenic therapy, 8-10 November 1999, Milan, Italy. Acta Histochemica 102(2): 117-127, 2000

The European School of Oncology Conference on Biological Basis for Antiangiogenetic Therapy, Milan Italy, November 8-10, 1999. International Journal of Biological Markers 14(4): 278-326, 1999

The biological basis for antiangiogenic therapy. European Journal of Cancer 36(15): 1913-1918, 2000

Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Investigational New Drugs 28(2): 199-202, 2010

Antiangiogenic therapy: more promise and, yet again, more questions. Journal of Clinical Oncology 21(21): 3897-3899, 2003

The evasive promise of antiangiogenic therapy. Journal of Hepatology 51(5): 970-972, 2009

The promise of antiangiogenic therapy for ovarian cancer. Cancer Biology and Therapy 8(23): 2273-2274, 2010

The promise of antiangiogenic therapy for ovarian cancer. Cancer Biology & Therapy 8(23): 2271-2272, 2009

Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: a novel antiangiogenic therapy. Biochemical and Biophysical Research Communications 413(1): 128-135, 2011

Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge. Current Pharmaceutical Design 13(35): 3545-3558, 2007

Antiangiogenic therapy in malignant glioma: promise and challenge. Current Pharmaceutical Design 13(35): 3545-3558, 2008

Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?. Annals of Oncology 22(6): 1247-1249, 2011

COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Science Translational Medicine 6(242): 242ra84, 2015

Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). Mathematical Biosciences 191(2): 159-184, 2004

An inducible hepatocellular carcinoma model for preclinical evaluation of antiangiogenic therapy in adult mice. Cancer Research 74(15): 4157-4169, 2015